Literature DB >> 21253762

Glioblastoma stem cells.

Ghazaleh Tabatabai1, Michael Weller.   

Abstract

Glioblastomas are highly malignant primary brain tumors with one of the worst survival rates among all human cancers. With a more profound understanding of the cellular and molecular mechanisms of tumor initiation and acquired resistance to conventional radio- and chemotherapy, novel therapeutic targets might be discovered to optimize therapeutic approaches. In this regard, the identification of a small cellular subpopulation, called glioblastoma stem cell or stem-like cells or glioma-initiating cells or brain tumor propagating cells, has gained attention. In this article, we briefly summarize the current state of knowledge about this tumor cell population and discuss future directions for basic and clinical research.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21253762     DOI: 10.1007/s00441-010-1123-0

Source DB:  PubMed          Journal:  Cell Tissue Res        ISSN: 0302-766X            Impact factor:   5.249


  34 in total

Review 1.  Unique biology of gliomas: challenges and opportunities.

Authors:  Stacey Watkins; Harald Sontheimer
Journal:  Trends Neurosci       Date:  2012-06-08       Impact factor: 13.837

Review 2.  The study of glioma by xenotransplantation in zebrafish early life stages.

Authors:  Miloš Vittori; Helena Motaln; Tamara Lah Turnšek
Journal:  J Histochem Cytochem       Date:  2015-06-24       Impact factor: 2.479

3.  CAMTA1 is a novel tumour suppressor regulated by miR-9/9* in glioblastoma stem cells.

Authors:  Daniel Schraivogel; Lasse Weinmann; Dagmar Beier; Ghazaleh Tabatabai; Alexander Eichner; Jia Yun Zhu; Martina Anton; Michael Sixt; Michael Weller; Christoph P Beier; Gunter Meister
Journal:  EMBO J       Date:  2011-08-19       Impact factor: 11.598

4.  Multiscale Modeling of Glioblastoma Suggests that the Partial Disruption of Vessel/Cancer Stem Cell Crosstalk Can Promote Tumor Regression Without Increasing Invasiveness.

Authors:  Huaming Yan; Monica Romero-Lopez; Hermann B Frieboes; Christopher C W Hughes; John S Lowengrub
Journal:  IEEE Trans Biomed Eng       Date:  2016-10-07       Impact factor: 4.538

5.  A disintegrin and metalloproteinases 10 and 17 modulate the immunogenicity of glioblastoma-initiating cells.

Authors:  Fabian Wolpert; Isabel Tritschler; Alexander Steinle; Michael Weller; Günter Eisele
Journal:  Neuro Oncol       Date:  2013-12-09       Impact factor: 12.300

6.  Frontiers in Suicide Gene Therapy of Cancer.

Authors:  Marek Malecki
Journal:  J Genet Syndr Gene Ther       Date:  2012-10-22

7.  EGCG inhibits properties of glioma stem-like cells and synergizes with temozolomide through downregulation of P-glycoprotein inhibition.

Authors:  Yong Zhang; Shao-Xiang Wang; Ji-Wei Ma; Hai-Ying Li; Jie-Cheng Ye; Si-Ming Xie; Bin Du; Xue-Yun Zhong
Journal:  J Neurooncol       Date:  2014-08-31       Impact factor: 4.130

8.  Glioma-initiating cell elimination by metformin activation of FOXO3 via AMPK.

Authors:  Atsushi Sato; Jun Sunayama; Masashi Okada; Eriko Watanabe; Shizuka Seino; Keita Shibuya; Kaori Suzuki; Yoshitaka Narita; Soichiro Shibui; Takamasa Kayama; Chifumi Kitanaka
Journal:  Stem Cells Transl Med       Date:  2012-11-15       Impact factor: 6.940

9.  Interleukin-1β and transforming growth factor-β cooperate to induce neurosphere formation and increase tumorigenicity of adherent LN-229 glioma cells.

Authors:  Lei Wang; Ziyan Liu; Sivasai Balivada; Tej Shrestha; Stefan Bossmann; Marla Pyle; Loretta Pappan; Jishu Shi; Deryl Troyer
Journal:  Stem Cell Res Ther       Date:  2012-02-10       Impact factor: 6.832

10.  Targeting JNK for therapeutic depletion of stem-like glioblastoma cells.

Authors:  Ken-ichiro Matsuda; Atsushi Sato; Masashi Okada; Keita Shibuya; Shizuka Seino; Kaori Suzuki; Eriko Watanabe; Yoshitaka Narita; Soichiro Shibui; Takamasa Kayama; Chifumi Kitanaka
Journal:  Sci Rep       Date:  2012-07-19       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.